The current first-line standard of care (SoC) for NSCLC harbouring HER2 alterations consists of platinum-based chemotherapy combined with immune-checkpoint inhibitor (ICI) [25]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.